Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats

Basit Öğe Kaydı
dc.authorwosidAktas, Cevat/D-8468-2011
dc.contributor.authorKanter, Mehmet
dc.contributor.authorSen, Saniye
dc.contributor.authorDonmez, Salim
dc.contributor.authorAktas, Cevat
dc.contributor.authorUstundag, Sedat
dc.contributor.authorErboga, Mustafa
dc.date.accessioned2024-06-12T11:07:16Z
dc.date.available2024-06-12T11:07:16Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this study was designed to investigate the possible beneficial effects of the angiotensin (ang) II T-1 (AT(1)) receptor blocker, irbesartan (Irb), and the alpha lipoic acid (ALA) in streptozotocin (STZ)-induced diabetic nephropathy (DNP) in rats. The rats were randomly allotted into one of five experimental groups: A, control; B, diabetic untreated; C, diabetic treated with Irb; D, diabetic treated with ALA; and E, diabetic treated with Irb + ALA; each group contains 10 animals. B, C, D, and E groups received STZ. Diabetes was induced in four groups by a single intraperitoneal injection of STZ (50 mg/kg, freshly dissolved in 5 mmol/L citrate buffer, pH 4.5). The rats in Irb-, ALA-, and Irb + ALA-treated groups were given Irb (5 mg/kg), ALA (in a dose of 3 mg/kg), and Irb + ALA (in a dose of 2.5 + 1.5 mg/kg) once a day orally by using intragastric intubation for 12 weeks starting 2 days after STZ injection, respectively. Treatment with ALA and especially Irb reduced the glomerular size; thickening of capsular, glomerular, and tubular basement membranes; increased amounts of mesangial matrix and tubular dilatation as compared with diabetic-untreated rats. Notably, the better effects were obtained when Irb and ALA were given together. We conclude that Irb, ALA, and especially Irb + ALA therapy causes renal morphologic improvement after STZ-induced diabetes in rats. We believe that further preclinical research into the utility of Irb and ALA treatment, alone or its combination, may indicate its usefulness as a potential treatment in DNP.en_US
dc.identifier.doi10.3109/08860221003646360
dc.identifier.endpage505en_US
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue4en_US
dc.identifier.pmid20446791en_US
dc.identifier.scopus2-s2.0-77952174536en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage498en_US
dc.identifier.urihttps://doi.org/10.3109/08860221003646360
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21975
dc.identifier.volume32en_US
dc.identifier.wosWOS:000277388400016en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIrbesartanen_US
dc.subjectAlpha Lipoic Aciden_US
dc.subjectTGF-Beta(1)en_US
dc.subjectInosen_US
dc.subjectDiabetic Nephropathyen_US
dc.subjectGrowth-Factor-Betaen_US
dc.subjectConverting Enzyme-Inhibitionen_US
dc.subjectOxidative Stressen_US
dc.subjectKidney-Diseaseen_US
dc.subjectNigella-Sativaen_US
dc.subjectCell Damageen_US
dc.subjectExpressionen_US
dc.subjectReceptoren_US
dc.subjectMellitusen_US
dc.titleProtective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu